Fintech Funding, May–June 2026: AI Stories Need Operating Proof
Fintech returned to large-round territory in May and June, but the strongest financings paired AI positioning with distribution, revenue, or embedded workflow evidence.
Startup Funding Guides & Investor Research
Raising startup funding requires matching your stage, traction, and sector to the right investors. Our startup funding resources cover everything from first checks to growth rounds — with actionable guidance for founders navigating today's market.
Startup Funding Essentials
- Stage alignment: Seed, Series A, and growth investors have different risk and return profiles
- Investor targeting: Thesis fit, portfolio overlap, and check-size compatibility
- Fundraising process: Decks, data rooms, diligence, and term negotiation
- Market timing: When to raise, how much to raise, and runway planning
Explore startup funding articles to sharpen your raise and find investors who fit your company.
Related Articles (825 articles)
-
-
Defense Tech Funding, May–June 2026: Production and Procurement Matter
Defense financings ranged from Anduril's mega-round to drones, countermeasures, and space systems; the recurring diligence questions are procurement, manufacturing, and delivery.
-
Cybersecurity Funding, May–June 2026: The AI Trust Layer
Security funding concentrated around data governance, agent identity, and the controls required to deploy AI inside enterprise workflows.
-
Crypto and Blockchain Infrastructure Funding, May–June 2026: Rails Over Hype
The May–June crypto funding sample favored stablecoin infrastructure, digital-asset rails, and financial products with identifiable users and regulatory constraints.
-
Climate and Energy Funding, May–June 2026: Capital Follows Deployment
Climate and energy financings favored storage, fusion, grid software, and infrastructure with a clear path to deployment, contracts, or manufacturing.
-
Biotech and Healthtech Funding, May–June 2026: Clinical Evidence Beats Platform Labels
Biotech and healthtech funding favored clinical, data, and workflow companies with identifiable milestones; the round table is not a substitute for asset-level diligence.